

Application/Control No.: 10/693042
Art Unit: 1647

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method for treating the secondary damage resulting from spinal cord injury, which comprises administering a therapeutically effective amount of *beta interferon* or a biosimilar analogue thereof.
2. (currently amended) The method as recited in claim 1, wherein the *beta interferon* or biosimilar analogue thereof is commercially available and is approved by the FDA for the treatment of multiple sclerosis (MS).
3. (currently amended) The method as recited in claim 2, wherein the *beta interferon* or biosimilar analogue thereof is administered as prescribed for the treatment of MS.
4. (currently amended) The method as recited in claim 1, wherein ~~either~~ Betasron, ~~or~~ Avonex, Rebif or Cinnovex is administered.
5. (original) The method as recited in any one of claims 2-4, wherein the commercially available *beta interferon* is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.
6. (original) The method as recited in claim 5, wherein the *beta interferon* is administered starting at about the 11th day or later after injury.
7. (original) The method as recited in claim 5, wherein the *beta interferon* is administered starting at the 4th week or later after injury.
8. (currently amended) A method of ~~preventing~~ halting or attenuating the progressive chronic inflammation and demyelination resulting from spinal cord injury, which comprises administering a therapeutically effective amount of *beta interferon* or a biosimilar analogue thereof.
9. (currently amended) The method as recited in claim 8, wherein the *beta interferon* or biosimilar analogue thereof is commercially available and is approved by the FDA for the treatment of MS.
10. (currently amended) The method as recited in claim 9, wherein the *beta interferon* or biosimilar analogue thereof is administered as prescribed for the treatment of MS.
11. (currently amended) The method as recited in claim 8, wherein ~~either~~ Betasron, ~~or~~ Avonex, Rebif or Cinnovex is administered.

Application/Control No.: 10/693042

Art Unit:

1647

12. (original) The method as recited in any one of claims 9-11, wherein the commercially available *beta interferon* is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.
13. (original) The method as recited in claim 12, wherein the *beta interferon* is administered starting at about the 11th day or later after injury.
14. (original) The method as recited in claim 12, wherein the *beta interferon* is administered starting at the 4th week or later after injury.
15. (currently amended) A method for therapy and rescue of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering a therapeutically effective amount of *beta interferon* or ~~as~~ a biosimilar analogue thereof.
16. (currently amended) The method as recited in claim 15, wherein the *beta interferon* or biosimilar analogue thereof is commercially available and is approved by the FDA for the treatment of MS.
17. (currently amended) The method as recited in claim 16, wherein the *beta interferon* or biosimilar analogue thereof is administered as prescribed for the treatment of MS.
18. (currently amended) The method as recited in claim 15, wherein either Betaseron, or Avonex, Rebif or Cinnovex is administered.
19. (original) The method as recited in any one of claims 16-18, wherein the commercially available *beta interferon* is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.
20. (original) The method as recited in claim 19, wherein the *beta interferon* is administered starting at about the 11th day or later after injury.
21. (original) The method as recited in claim 19, wherein the *beta interferon* is administered starting at the 4th week or later after injury.
22. (currently amended) A method for repair and rescue of the neurologic function of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering a therapeutically effective amount of *beta interferon* or ~~as~~ a biosimilar analogue thereof.
23. (currently amended) The method as recited in claim 22, wherein the *beta interferon* or biosimilar analogue thereof is commercially available and is approved by the FDA for the treatment of MS.

Application/Control No.: 10/693042

Art Unit: 1647

24. (currently amended) The method as recited in claim 23, wherein the *beta interferon* or biosimilar analogue thereof is administered as prescribed for the treatment of MS.
25. (currently amended) The method as recited in claim 22, wherein either Betaseron, ~~or~~ Avonex, Rebif or Cinnovex is administered.
26. (original) The method as recited in any one of claims 23-25, wherein the commercially available *beta interferon* is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.
27. (original) The method as recited in claim 26, wherein the *beta interferon* is administered starting at about the 11th day or later after injury.
28. (original) The method as recited in claim 26, wherein the *beta interferon* is administered starting at the 4th week or later after injury.